[196 Pages Report] The Castleman Disease Treatment Market size was estimated at USD 294.33 million in 2023 and expected to reach USD 334.15 million in 2024, at a CAGR 13.62% to reach USD 719.87 million by 2030.
Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.
Multicentric Castleman’s disease (MCD) refers to the disease condition that causes lymph node enlargement in multiple regions of the patient’s body. There are three categories of MCD-Polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes (POEMS)-associated MCD, human herpesvirus-8 (HHV-8)-associated MCD, and idiopathic MCD. Treatment for multicentric Castleman disease generally involves medicines and other therapies to control cell overgrowth. Specific treatment may also depend on the extent of the disease and whether the patient has human immunodeficiency virus infection (HIV), human herpesvirus-8 (HHV-8) infection, or both. Unicentric Castleman’s disease (UCD) refers to a disorder that affects a single lymph node in the patient’s body, usually in the chest or abdomen. Unicentric Castleman disease can be treated by surgically removing the diseased lymph node.
Angiofollicular lymph node hyperplasia is associated with prolonged fever, anemia, weight loss, splenomegaly, and hypergammaglobulinemia. Angiomatous lymphoid hamartomas or pseudolymphomas have been reported most commonly within the chest and are usually mistaken for thymic tumors of lymphomatous tissue. It is a rare manifestation where immunomodulatory treatment is often utilized. Castleman tumor is an unusual mediastinal lymph node hyperplasia that resembles thymoma. The characteristic histologic characteristics include an onion skin arrangement of the lymphocytes in nodules and an unusual vasculature with marked capillary proliferation. Giant benign lymphoma is the most common non-epithelial benign tumor occurring in the large intestine. It is usually observed in the rectum as a single reddish-purple or grey, rounded polyp varying in diameter from a few millimeters to 3–4 centimeters. Giant lymph node hyperplasia is a nonneoplastic lymphoproliferative disorder of unknown etiology that is usually observed in the chest. The morphological recognition of this disease is based on a combination of various histological features. Angiomyomatous hamartoma of lymph nodes (AMH-LN) refers to an unusual benign proliferation of smooth muscle, blood vessels, collagenous stroma, and adipocytes.
Antiviral medications are used to target harmful viruses. The antiviral drugs are used to ease disease symptoms. Chemotherapy refers to the practice of utilizing a drug or chemical treatment to kill fast-growing cancer cells in a patient's body. Low-dose single-agent chemotherapy treatment options, such as daily oral etoposide59 or intermittent etoposide or vinblastine, have been utilized for MCD. Corticosteroids are powerful anti-inflammatory drugs that can mitigate disease symptoms. Systemic corticosteroids can provide symptomatic relief but do not predictably reduce tumor size. Immunotherapy takes advantage of the body's natural defenses to fight the disease. Monoclonal antibodies refer to proteins made in a laboratory that bind to one pathogenic antigen only. In HHV–8–associated MCD, treatment with rituximab is highly effective. For some patients with HIV infection, antiretroviral therapy (ART) should be included with the rituximab. Radiation therapy refers to a cancer treatment that uses bursts of radiation to target and kill cancer cells and shrink tumors. In unicentric Castleman disease, radiotherapy radiation therapy is a viable treatment option because of its high response rates.
Ambulatory surgical centers (ASCs) refer to modern medical facilities that aim to provide same-day surgical care, including diagnostic and preventive procedures. These centers have gradually become popular for the treatment of Castleman disease due to their perceived medical efficiency and the reduced waiting times involved in scheduling a treatment. The hospital segment continues to remain a significant contributor to Castleman disease treatment owing to the intensity of care that comes with the complex nature of disease management.
The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.
The FPNV Positioning Matrix is pivotal in evaluating the Castleman Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
FDA Approves Tocilizumab Biosimilar Tofidence
The US Food and Drug Administration (FDA) approved Tofidence (tocilizumab-bavi) as the first biosimilar to Actemra (tocilizumab). Tofidence was developed through a partnership between Biogen and Bio-Thera Solutions. Tocilizumab is a monoclonal antibody that targets IL-6R, an immunosuppressant drug used for treating rheumatoid arthritis and systemic juvenile idiopathic arthritis in children. It is also approved for Castleman's disease, a rare benign tumor of B cells, in Japan. This approval signifies an important advancement in the treatment options available for Castleman's disease. [Published On: 2023-10-17]
Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
Chugai Pharmaceutical Co., Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare for an additional indication of treatment of Castleman Disease with their humanized anti-human IL-6 receptor monoclonal antibody, Actemra Intravenous Infusion. This expands the original indication for treating cytokine release syndrome induced by tumor-specific T-cell infusion therapy to incorporate other cancer treatments. [Published On: 2023-09-25]
Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
Medable Inc., a technology platform for patient-centered clinical trials, partnered with Every Cure, a non-profit organization established in collaboration with the Clinton Global Initiative. The objective of this partnership is to identify potential treatments for rare conditions, including Castleman disease. [Published On: 2023-01-04]
The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..
This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Disease Type
- Multicentric Castleman’s Disease
- Unicentric Castleman’s Disease
- Indication
- Angiofollicular Lymph Node Hyperplasia
- Angiomatous Lymphoid
- Castleman Tumor
- Giant Benign Lymphoma
- Giant Lymph Node Hyperplasia
- Hamartoma of the Lyphatics
- Treatment
- Antiviral Drugs
- Chemotherapy
- Corticosteroids
- Immunotherapy
- Monoclonal Antibodies
- Radiation Therapy
- Application
- Ambulatory Surgical Centers
- Hospitals
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Castleman Disease Treatment Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Castleman Disease Treatment Market?
- What are the technology trends and regulatory frameworks in the Castleman Disease Treatment Market?
- What is the market share of the leading vendors in the Castleman Disease Treatment Market?
- Which modes and strategic moves are suitable for entering the Castleman Disease Treatment Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Castleman Disease Treatment Market, by Disease Type
- Castleman Disease Treatment Market, by Indication
- Castleman Disease Treatment Market, by Treatment
- Castleman Disease Treatment Market, by Application
- Americas Castleman Disease Treatment Market
- Asia-Pacific Castleman Disease Treatment Market
- Europe, Middle East & Africa Castleman Disease Treatment Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 24]
- List of Tables [Total: 384]
- List of Companies Mentioned [Total: 30]
The Importance of Orphan Drug Designation:
Orphan drug designation is a regulatory tool that incentivizes the development of drugs that treat rare diseases. By granting orphan drug designation status, manufacturers of these drugs can receive financial benefits, tax credits, and prolonged market exclusivity to defray development costs. For Castleman disease patients, obtaining orphan drug status signifies a higher chance of acquiring access to life-changing treatments. This designation has launched several clinical trials as pharma manufacturers seek to bring new therapies to the market.
Understanding the Importance of FDA Approvals:
The FDA approval is a crucial step in bringing new treatments to the market. In Castleman disease, FDA approvals create a pathway for new therapies that have shown efficacy in treating the condition. Such approvals mean that the FDA confirms that a drug is safe and effective for the treatment of Castleman disease. Such approvals have significantly improved access to treatment options for Castleman disease patients.
Treatment Options for Castleman Disease Patients:
Standard treatment options for Castleman disease patients include chemotherapy, radiation therapy, and targeted therapy. As previously mentioned, some pharma manufacturers are already working toward bringing new treatments to the market. With technological advancements and increasing awareness of Castleman disease, patients stand to benefit from more treatment options in the future.
The Role of Medical Professionals:
Medical professionals play a central role in the development and approval of orphan drugs for Castleman disease. Various organizations have worked tirelessly to understand Castleman disease and improve patient outcomes. State-of-the-art medical facilities that focus on Castleman disease by analyzing patient information, symptoms, history, and other clinical details, medical professionals contribute to the efficacy of drug tests and work toward obtaining approvals for new drug therapies.
The Future of Castleman Disease Treatment:
The recent advancements in Castleman disease treatments have been significant. There is growing awareness about Castleman disease, and this has led to more organizations researching and developing new therapies. The importance of obtaining orphan drug designation and approvals for Castleman disease treatments cannot be overstated, and we can only expect more breakthroughs in the future.
Castleman disease is a rare, complex, and life-threatening disease that affects the body's lymphatic system. Patients with Castleman disease have limited treatment options, making the recent orphan drug designations and approvals significant. These designations and approvals have offered hope for better patient outcomes, and they pave the way for new therapies to hit the market. Medical professionals play a crucial role in understanding Castleman disease and improving patient outcomes. The future looks bright with increasing awareness of this condition. As pharma manufacturers continue to develop new drugs, medical professionals and patients alike remain hopeful for further progress in the treatment of Castleman disease.
- How big is the Castleman Disease Treatment Market?
- What is the Castleman Disease Treatment Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?